GSK_Annual_Report_2021

Notes to the Standalone Financial Statements for the year ended March 31, 2021 (contd.) Financial Statements GlaxoSmithKline Pharmaceuticals Limited 146 ( ` in lakhs) As at March 31, 2020 (o) Cross charges recoverable at the period end : GlaxoSmithKline Biologicals S.A., Belgium 30.41 GlaxoSmithKline Export Limited, U.K. 31.69 GlaxoSmithKline Research & Development Ltd, U.K. 21.57 GlaxoSmithKline Services Unlimited, U.K. 16.27 Glaxo Operations UK Limited, U.K. 19.65 GlaxoSmithKline Pharmaceutical Ltd., Sri Lanka 5.63 (iv) Details relating to persons referred to in item 1(iv) above: ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 1 Remuneration / commission / sitting fees 37,93.20 40,91.89 2 Payments under the long-term incentive plan 2,95.47 5,16.49 (v) Disclosure in respect of material transactions with persons referred to in item 1(iv) above: ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 (a) Remuneration / commission / sitting fees (Refer Note below): Mr. A. Vaidheesh - 9,47.67 Mr. S. Venkatesh 8,21.46 - Mr. A. Iyer 3,42.86 4,54.17 Mr. R. Krishnaswamy 5,01.22 2,60.48 Ms. P. Thakur 3,27.63 3,98.40 Ms. M. Priyam 1,24.19 4,13.37 (b) Payments made during the year under the long-term incentive plan (Refer Note below): Mr. A. Vaidheesh - 3,26.95 Ms. P. Thakur 27.89 35.36 Mr. R. Krishnaswamy 53.24 28.90 Mr. S. Dheri 26.48 31.82 Mr. A. Iyer 89.16 11.48 Mr. B. Kotak 43.36 - Note: Amounts are not comparable as they pertain to part of the year and/ or are recorded on cash payment basis.